The efficacy and safety of PD-1/PD-L1 inhibitors in breast cancer: a systematic review and meta-analysis

BACKGROUND: Immune checkpoint inhibition has been increasingly used in breast cancer therapy. Understanding the benefit and risk of programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors is critical for clinical practice. This study aims to determine the objective respo...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiao, Bo-Ya, Lin, Guo-He, Zhao, Yan-Xia, Wang, Bi-Cheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797420/
https://www.ncbi.nlm.nih.gov/pubmed/35117748
http://dx.doi.org/10.21037/tcr-19-3020

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797420/
https://www.ncbi.nlm.nih.gov/pubmed/35117748
http://dx.doi.org/10.21037/tcr-19-3020

Ejemplares similares